Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
74.85
+0.65 (0.88%)
At close: Oct 30, 2026, 4:00 PM EDT
76.29
+1.44 (1.92%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $173.91M in the quarter ending June 30, 2026, with 69.41% growth. This brings the company's total for the last twelve months to $606.33M, up 105.17% year-over-year. In the year 2025, Tarsus Pharmaceuticals had annual revenue of $451.36M with 146.71% growth. That makes Tarsus Pharmaceuticals the 10,164th largest company in the world by revenue and 2,163rd in the United States.
Revenue (ttm)
$606.33M
Revenue Growth
+105.17%
P/S Ratio
5.42
Revenue / Employee
$1,638,732
Employees
370
Market Cap
3.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 451.36M | 268.41M | 146.71% |
| Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
| Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
| Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
| Dec 31, 2021 | 57.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acadia Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 890.79M |
| IDEAYA Biosciences | 234.13M |
| Xenon Pharmaceuticals | 7.50M |
| Denali Therapeutics | 3.60M |
TARS News
- 1 day ago - Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 - GlobeNewsWire
- 2 days ago - Tarsus Pharmaceuticals price target lowered to $94 from $100 at Mizuho - TheFly
- 2 days ago - Tarsus Pharmaceuticals appoints Neera Clase as chief commercial officer - TheFly
- 2 days ago - Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer - GlobeNewsWire
- 17 days ago - Tarsus Pharmaceuticals files to sell 2.91M shares of common stock for holders - TheFly
- 4 weeks ago - Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs - TheFly
- 6 weeks ago - Tarsus Pharmaceuticals reinstated with an Overweight at Barclays - TheFly